ArticleAnti-cancer drugs2025

Benefit of switching to firmonertinib following almonertinib-induced interstitial pneumonitis in a patient with advanced non-small-cell lung cancer: a case report.

Lingying Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.